Latest Manufacturing And Distribution News

Page 2 of 10
ClearVue Technologies saw a 35% revenue decline to $161,000 and a $11 million net loss in FY2026, driven by a major operational overhaul and significant product certification efforts. Despite the financial setback, the company expanded into new markets and secured key commercial projects.
Sophie Babbage
Sophie Babbage
31 Aug 2026
Sea Forest Limited (ASX:SEA) reported a spectacular 486% surge in SeaFeed revenue for FY26, underpinned by 131,000 cattle committed, surpassing breakeven targets, and a robust $27.8 million cash buffer. The company advances its commercial footprint domestically and internationally, with carbon credit revenue set to kick off in late 2027.
Victor Sage
Victor Sage
28 Aug 2026
Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.
Ada Torres
Ada Torres
27 Aug 2026
Australian Dairy Nutritionals reported a 47% reduction in net loss for FY26, driven by a 66% revenue jump in its nutritional powders segment, which now makes up 70% of total revenue.
Victor Sage
Victor Sage
27 Aug 2026
Biome Australia has delivered a standout FY26 with sales up 30% to $23.9 million and net profit after tax soaring to $3.6 million, bolstered by a non-cash deferred tax asset. The company strengthened its balance sheet while expanding manufacturing and international distribution.
Ada Torres
Ada Torres
26 Aug 2026
Yowie Group's revenue declined in the first half of 2026 as it navigated supply chain shifts and cautious retail demand, but the company secured a significant Australian licensing deal and ended costly legacy litigation.
Victor Sage
Victor Sage
19 Aug 2026
Fletcher Building (ASX:FBU) reversed its FY25 loss with a $228 million net profit in FY26, driven by a 26% rise in EBIT and a $362 million reduction in net debt amid portfolio simplification and operational improvements.
Victor Sage
Victor Sage
19 Aug 2026
Radiopharm Theranostics is gearing up for a pivotal Phase 3 trial of its brain metastases imaging agent RAD101, following strong Phase 2b results and an upcoming FDA meeting to finalise trial design.
Ada Torres
Ada Torres
17 Aug 2026
Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.
Ada Torres
Ada Torres
31 July 2026
Pure One Corporation has made strides in zero-emission commercial vehicles with new battery-swap and electric models arriving in Australia, backed by a strengthened balance sheet from a $3.5 million tranche of Turquoise Group sale proceeds.
Victor Sage
Victor Sage
31 July 2026
ClearVue Technologies bolstered its balance sheet with a A$6 million capital raise while landing high-profile projects including Canva’s Sydney HQ and its first European contract in Cyprus. The company also advanced international expansion and achieved key certifications confirming product durability and safety.
Sophie Babbage
Sophie Babbage
31 July 2026
BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.
Victor Sage
Victor Sage
30 July 2026

Browse the archive

Full archive